Rossari Biotech Limited has announced a corporate name change for its wholly owned subsidiary operating in Dubai's financial free zone. The company informed stock exchanges about this regulatory compliance update on March 24, 2026.

Subsidiary Name Change Details

The company's wholly owned subsidiary has undergone a name modification as per local regulatory requirements:

Regulatory Compliance

The name change represents compliance with mandatory guidelines from the Dubai Multi Commodities Centre Authority. The company specifically noted that the modification pertains only to the suffix of the subsidiary's name, indicating a structural requirement rather than a fundamental business change.

Corporate Communication

Rossari Biotech fulfilled its disclosure obligations under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company communicated this development to both major Indian stock exchanges where its shares are listed.

The information has been made available on the company's official website at www.rossari.com for stakeholder reference. This transparency measure ensures all concerned parties have access to the updated subsidiary information.

Administrative Details

The formal communication was signed by Parul Gupta, Head - Company Secretary & Legal, with membership number A38895. The digital signature was authenticated on March 24, 2026, confirming the official nature of this corporate announcement.

Rossari Biotech Limited has concluded arbitration proceedings related to its material unlisted subsidiary Unitop Chemicals Private Limited, receiving the final award that resolves a dispute dating back to a 2021 share purchase agreement.

Arbitration Background and Timeline

The arbitration proceedings were initiated by existing shareholders of Unitop Chemicals Private Limited under a Share Purchase Agreement dated June 02, 2021. The sellers in the dispute included Barkur Dharmaraj Shetty, B.D. Shetty HUF, Saibala Dharmaraj Shetty, Rajeshwari D Shetty, Jeenanath Dharmaraj Shetty, and Balakrishna Barkur Shetty.

The company had previously disclosed the initiation of these proceedings on December 13, 2023. The Arbitral Tribunal passed its final award on January 21, 2026, which was received by the company on January 28, 2026.

Key Arbitration Outcomes

The arbitration tribunal delivered a mixed verdict that addressed claims from both parties:

The tribunal specifically dismissed the sellers' claim concerning their exercise of the Put Option under the Share Purchase Agreement, which would have required Rossari Biotech to purchase third tranche shares in Unitop Chemicals Private Limited.

Financial Impact Assessment

The company has assessed the financial implications of the arbitration award as limited in scope. The primary financial obligation consists of the tax refund amount of INR 97,90,617 along with applicable interest at 12% per annum, plus the company's share of arbitration costs.

Rossari Biotech has stated that this financial liability is not expected to have any material impact on the company's overall financials. The award remains confidential as noted in the regulatory disclosure.

Regulatory Compliance and Next Steps

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company filed the update in compliance with SEBI Master Circular dated November 11, 2024, and Circular dated December 31, 2024.

Rossari Biotech indicated it is currently studying the arbitration award and considering its available options regarding the tribunal's decision. The company maintains its registered office in Mumbai and operates manufacturing facilities in Silvassa and Gujarat, focusing on home, personal care, performance chemicals, textile specialty chemicals, and animal health and nutrition segments.